Scholarlink

The approval of upadacitinib, an oral selective inhibitor of Janus kinase 1 (JAK1), marks a significant advancement in the treatment of moderate-to-severe atopic dermatitis (AD). By targeting JAK1 specifically, upadacitinib reduces the generation of pro-inflammatory cytokines that are intricately involved in the pathogenesis of AD. The administration of this compound demonstrates a dose-dependent inhibition of JAK1/JAK2-induced signal transducer and activator of transcription protein 3 (STAT3) phosphorylation as well as JAK1/JAK3-induced STAT5 phosphorylation. This section provides a thorough review of upadacitinib, encompassing its chemical structure, pharmacokinetic and pharmacodynamic properties, and safety considerations.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Selective JAK Inhibitor: Upadacitinib (JAK1-Selective)

  • 章节

  • 发表日期：

    2025年

查看全文
  • Ümmühan Şeker,
  • Kenan Aydoğan

摘要

The approval of upadacitinib, an oral selective inhibitor of Janus kinase 1 (JAK1), marks a significant advancement in the treatment of moderate-to-severe atopic dermatitis (AD). By targeting JAK1 specifically, upadacitinib reduces the generation of pro-inflammatory cytokines that are intricately involved in the pathogenesis of AD. The administration of this compound demonstrates a dose-dependent inhibition of JAK1/JAK2-induced signal transducer and activator of transcription protein 3 (STAT3) phosphorylation as well as JAK1/JAK3-induced STAT5 phosphorylation. This section provides a thorough review of upadacitinib, encompassing its chemical structure, pharmacokinetic and pharmacodynamic properties, and safety considerations.